Lanctot, K. L. et al. Neuropsychiatric signs and symptoms of Alzheimer’s disease: New treatment paradigms. Alzheimers Dement (N Y) 3, 440–449, https://doi.org/10.1016/j.trci.2017.07.001 (2017).
Zhao, Q. F. et al. The prevalence of neuropsychiatric symptoms in Alzheimer’s disease: Systematic review and meta-analysis. J Affect Disord 190, 264–271, https://doi.org/10.1016/j.jad.2015.09.069 (2016).
Rabins, P. V. et al. Predictors of progression to severe Alzheimer’s disease in an incidence sample. Alzheimers Dement 9, 204–207, https://doi.org/10.1016/j.jalz.2012.01.003 (2013).
Martinez, A. Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs. Med Res Rev 28, 773–796, https://doi.org/10.1002/med.20119 (2008).
Frame, S. & Cohen, P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 359, 1–16 (2001).
Frame, S.,…
